Advanced gastrointestinal stromal tumors (GISTs): A short review (notice n° 1573140)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02367cam a2200253 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20251214025845.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Letissier, Octave |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Advanced gastrointestinal stromal tumors (GISTs): A short review |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2025.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 77 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The management of advanced gastrointestinal stromal tumors (GISTs) has progressed in recent years, as highlighted by the 2024 update of the Thésaurus National de Cancérologie Digestive (TNCD). Biopsy or circulating tumor DNA (ctDNA) testing for mutations in KIT and PDGFRA is essential. Imatinib remains the cornerstone of treatment in advanced GIST with KIT mutation, at the standard dose of 400 mg/d or 800 mg/d in the presence of exon 9 mutation. Secondary surgical resection may be considered after 6 to 12 months of imatinib in unresectable non-metastatic GIST. After progression on imatinib 400 mg/d, and after checking for compliance and potential drug interactions, an imatinibemia measurement and ctDNA analysis are used to rule out imatinib underdosing and to look for imatinib-resistant mutations in KIT. Options include increasing the dose to 800 mg/d or switching to a different tyrosine kinase inhibitor, with sunitinib as a priority. Regorafenib and ripretinib are the standard-of-care third- and fourth-line treatments respectively. Inoperable or metastatic GISTs with PDGFRA p.D842V mutation should be treated with avapritinib. GISTs without KIT or PDGFRA mutations are often slow-growing, and destruction or excision of metastases may be indicated. Some specific GISTs (NTRK fusion, BRAFV600E mutation, etc.) may benefit from targeted treatments. Whatever the line of treatment, it is advisable to ask a NETSARC network center for information on ongoing or future trials. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Le Sourd, Samuel |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lièvre, Astrid |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Boisteau, Émeric |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Edeline, Julien |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hautefeuille, Vincent |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bouché, Olivier |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Perrin, Christophe |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pracht, Marc |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 32 | 7 | 2025-09-23 | p. 669-676 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2025-7-page-669?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2025-7-page-669?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux